The Autoimmune Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

Published by: Business Insights

Published: Apr. 1, 2009 - 208 Pages

Table of Contents

Executive Summary

Epidemiology of autoimmune diseases

Global market analysis

Pipeline analysis

Competitive landscape

Chapter 1 Scope and methodology

Scope

Key autoimmune indications covered in this report:

Methodology

Chapter 2 Epidemiology of autoimmune

diseases

Summary

Introduction

Osteoarthritis

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Rheumatoid arthritis

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Crohn’s disease

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Systemic lupus erythematosus

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Ulcerative colitis

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Multiple sclerosis

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Chapter 3 Global market analysis

Summary

Introduction

Market analysis by country

Trends in generics usage and licensing

Market analysis by drug class

Leading brands dynamics

Key events in the autoimmune market

Enbrel growth slowing as it faces stiff competition from Humira

RoActemra receives positive opinion in Europe for the treatment of

RA

NICE admits previous guidance around sequential use of anti-TNF

therapies in RA is unfair

Study shows prohibitive cost of MS treatment

Mayo Clinic collaborates to advance Crohn's treatment

Arthritis research shows better disease management is more

important than the use of drugs

CellCept’s off-label use in lupus continues to increase

Immunosuppressants

Competitive dynamics of immunosuppressants

Leading brands of immunosuppressants

Key brands analysis

Clinical developments

Immunosuppressants sales forecasts to 2013

Specific anti-rheumatic agents

Competitive dynamics of specific anti-rheumatic agents

Leading brands of specific anti-rheumatic agents

Key brands analysis

Specific anti-rheumatic agents sales forecasts to 2013

Non-steroidal plain anti-rheumatics

Competitive dynamics of non-steroidal plain anti-rheumatics

Leading brands of non-steroidal plain anti-rheumatics

Key brands analysis

Non-steroidal plain anti-rheumatics sales forecasts to 2013

Topical anti-rheumatics

Competitive dynamics of topical anti-rheumatics

Leading brands of topical anti-rheumatics

Topical anti-rheumatic sales forecasts to 2013

Coxibs

Competitive dynamics of coxibs

Leading brands of coxibs

Key brands analysis

Coxibs sales forecasts to 2013

Non-steroidal (combinational) anti-rheumatics

Competitive dynamics of non-steroidal (combinational) anti-rheumatics

Leading brands of non-steroidal (combinational) anti-rheumatics

Non-steroidal (combinational) anti-rheumatics sales forecasts to 2013

Anti-rheumatic corticosteroids

Competitive dynamics of anti-rheumatic corticosteroids

Leading brands of anti-rheumatic corticosteroids

Anti-rheumatic corticosteroids sales forecasts to 2013

Total autoimmune sales forecasts to 2013

Chapter 4 Pipeline analysis

Summary

Introduction

Key trends in R&D

Biologics

Combination drugs

Aggressive medical therapy becoming the standard of care

TNF inhibitors has a strong presence in autoimmune market

Efforts to develop fully human monoclonal antibodies

The autoimmune pipeline

Leading drugs in development

Profiles of key pipeline products

Phase III compounds

Licofelone (ML3000) - Merckle GmbH

Ocrelizumab (R-1594) - Genentech, Biogen IDEC, Chugai and

Roche

LymphoStat-B (belimumab) - Human Genome Sciences (HGS) and

GSK

Ofatumumab (HuMax-CD20) - Genmab and GSK

Fingolimod (FTY-720) - Novartis/Mitsubishi Tanabe Pharma

Fampridine-SR - Acorda

Campath (alemtuzumab) - Genzyme and Bayer Schering Pharma

Recently approved/marketed drugs

Cimzia (certolizumab pegol) - UCB

Golimumab (CNTO-148) - Centocor/Schering-Plough

Actemra (tocilizumab) - Roche/Chugai

Tysabri (natalizumab) - Elan/Biogen Idec

Mesavance (mesalamine) - Shire

Pipeline forecasts

Factors affecting forecasts

Autoimmune pipeline forecast

Chapter 5 Competitive landscape

Summary

Introduction

Sales performance of leading players

Detailed analysis of leading autoimmune players

Amgen

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Abbott

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Johnson and Johnson

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Pfizer

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Novartis

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Wyeth

Overview

Wyeth and Pfizer

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Roche

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Astellas

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Chapter 6 Appendix

IMS Data

Immunosuppressive agents

L4A: Immunosuppressive agents

Musculo-skeletal system

M1: Anti-inflammatory and anti-rheumatic products

M2: Topical anti-rheumatics

Licensing status as per IMS Health

Original brand

Other brand

Licensed brand

Not-coded product

Unbranded/ generic product

Glossary

Index

List of Figures

Figure 3.1: Worldwide autoimmune market share by geography, 2007

Figure 3.2: Sales of types of autoimmune brands, 2007

Figure 4.3: Prevailing treatment approach for arthritis (OA and RA)

Figure 4.4: The autoimmune pipeline by indication and stage of development, 2007 116

Figure 4.5: Leading recently launched products and late-stage R&D in the autoimmune disorders market, 2008

Figure 5.6: Competitive dynamics of the leading players in the global autoimmune market, 2007

Figure 5.7: Amgen’s autoimmune sales by drug class, 2007

Figure 5.8: Abbott’s autoimmune sales by drug class, 2007

Figure 5.9: J&J’s autoimmune sales by drug class, 2007

Figure 5.10: Pfizer’s autoimmune sales by drug class, 2007

Figure 5.11: Novartis’ autoimmune sales by drug class, 2007

Figure 5.12: Wyeth’s autoimmune sales by drug class, 2007

Figure 5.13: Roche’s autoimmune sales by drug class, 2007

Figure 5.14: Astellas autoimmune sales by drug class, 2007

List of Tables

Table 2.1: Estimated prevalence of autoimmune diseases across seven major markets, 2007

Table 2.2: Estimated prevalence of OA across seven major markets, 2007

Table 2.3: Forecast epidemiology of OA across seven major markets, 2007-13

Table 2.4: Estimated prevalence of RA across seven major markets, 2007

Table 2.5: Forecast epidemiology of RA across seven major markets, 2007-13

Table 2.6: Estimated prevalence of CD across seven major markets, 2007

Table 2.7: Forecast epidemiology of CD across seven major markets, 2007-13

Table 2.8: Estimated prevalence of lupus across seven major markets, 2007

Table 2.9: Forecast epidemiology of lupus across seven major markets, 2007-13

Table 2.10: Estimated prevalence of UC across seven major markets, 2007

Table 2.11: Forecast epidemiology of UC across seven major markets, 2007-13

Table 2.12: Estimated prevalence of MS across seven major markets, 2007

Table 2.13: Forecast epidemiology of MS across seven major markets, 2007-13

Table 3.14: Worldwide autoimmune sales by countries, 2007

Table 3.15: Breakdown of the global autoimmune market by drug class, 2007

Table 3.16: Leading brands in the global autoimmune market, 2007

Table 3.17: Leading immunosuppressant brands in the global autoimmune market, 2006-07

Table 3.18: Remicade launch status in major markets

Table 3.19: Immunosuppressants sales forecast, 2007-13

Table 3.20: Leading specific anti-rheumatic brands in the global autoimmune market, 2006-07

Table 3.21: Enbrel launch status in major markets

Table 3.22: Specific anti-rheumatic agents sales forecast, 2007-13

Table 3.23: Leading non-steroidal plain anti-rheumatic brands in the global autoimmune market, 2006-07

Table 3.24: Non-steroidal plain anti-rheumatics sales forecast, 2007-13

Table 3.25: Leading topical anti-rheumatic brands in the global autoimmune market, 2006-07

Table 3.26: Topical anti-rheumatic sales forecast, 2007-13

Table 3.27: Leading coxib brands in the global autoimmune market, 2006-07

Table 3.28: Coxibs sales forecast, 2007-13

Table 3.29: Leading non-steroidal (combinational) anti-rheumatic brands in the global autoimmune market, 2006-07

Table 3.30: Non-steroidal (combinational) anti-rheumatics sales forecast, 2007-13

Table 3.31: Leading anti-rheumatic corticosteroid brands in the global autoimmune market, 2006- 07

Table 3.32: Anti-rheumatic corticosteroids sales forecast, 2007-13

Table 3.33: Therapeutic sales forecasts by drug class, 2007-13

Table 4.34: An overview of Licofelone

Table 4.35: An overview of Ocrelizumab

Table 4.36: An overview of LymphoStat-B

Table 4.37: An overview of Ofatumumab

Table 4.38: An overview of FTY-720

Table 4.39: An overview of Fampridine-SR

Table 4.40: Fampridine-SR Phase III data

Table 4.41: An overview of Campath

Table 4.42: An overview of Cimzia

Table 4.43: An overview of Golimumab

Table 4.44: An overview of Actemra

Table 4.45: An overview of Tysabri

Table 4.46: An overview of Mesavance

Table 4.47: Autoimmune pipeline sales forecasts, 2007-13

Table 5.48: Leading players in the global autoimmune market, 2007-13 ($m)

Table 5.49: Amgen’s autoimmune product portfolio, 2006-07

Table 5.50: Amgen’s autoimmune R&D product pipeline, 2008

Table 5.51: Abbott’s autoimmune product portfolio, 2006-07

Table 5.52: Abbott’s autoimmune R&D product pipeline, 2008

Table 5.53: J&J’s autoimmune product portfolio, 2006-07

Table 5.54: J&J’s autoimmune R&D product pipeline, 2008

Table 5.55: Pfizer’s autoimmune product portfolio, 2006-07

Table 5.56: Pfizer’s autoimmune R&D product pipeline, 2008

Table 5.57: Novartis’ autoimmune product portfolio, 2006-07

Table 5.58: Novartis’ autoimmune R&D product pipeline, 2008

Table 5.59: Wyeth’s autoimmune product portfolio, 2006-07

Table 5.60: Wyeth’s autoimmune R&D product pipeline, 2008

Table 5.61: Roche’s autoimmune product portfolio, 2006-07

Table 5.62: Roche’s autoimmune R&D product pipeline, 2008

Table 5.63: Astellas’s autoimmune product portfolio, 2006-07

Table 5.64: Astellas’s autoimmune R&D product pipeline, 2008

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.